NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Short Interest Update

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 38,703 shares, a growth of 219.1% from the July 15th total of 12,127 shares. Based on an average daily volume of 34,041 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.5% of the company’s stock are short sold.

Analyst Ratings Changes

A number of research analysts recently issued reports on NMTC shares. LADENBURG THALM/SH SH increased their price objective on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings upgraded NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, NeuroOne Medical Technologies currently has an average rating of “Hold” and a consensus target price of $11.67.

Insider Activity

In other news, Director Mark Christianson sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total value of $31,800.00. Following the sale, the director directly owned 20,692 shares in the company, valued at $65,800.56. The trade was a 32.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 11.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after buying an additional 375,639 shares in the last quarter. Bard Associates Inc. bought a new stake in NeuroOne Medical Technologies during the second quarter worth $929,000. Essex Investment Management Co. LLC bought a new stake in NeuroOne Medical Technologies during the fourth quarter worth $143,000. Virtu Financial LLC acquired a new stake in NeuroOne Medical Technologies in the third quarter valued at $88,000. Finally, Goldman Sachs Group Inc. acquired a new stake in NeuroOne Medical Technologies in the first quarter valued at $84,000. 16.07% of the stock is owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Stock Performance

NeuroOne Medical Technologies stock traded up $0.28 during mid-day trading on Thursday, reaching $1.80. The company’s stock had a trading volume of 212,478 shares, compared to its average volume of 45,380. NeuroOne Medical Technologies has a 12 month low of $1.42 and a 12 month high of $6.96. The business’s 50 day simple moving average is $2.60 and its 200 day simple moving average is $3.82. The company has a market capitalization of $15.63 million, a price-to-earnings ratio of -2.11 and a beta of 0.61.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.30. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. The firm had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $2.55 million. As a group, sell-side analysts expect that NeuroOne Medical Technologies will post -0.36 EPS for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.